Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novartis Ag ADR (NY: NVS )

110.52 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novartis Ag ADR

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Why Is $7B Valued Cancer Focused Exelixis Trading Lower Today?
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an  
Via Benzinga
Insufficient self-sufficiency of raw materials in Japan
Via AB Newswire
Topics Supply Chain
Exposures Supply Chain
Voyager Therapeutics stock pops 30% on deal with Novartis
Voyager Therapeutics Inc. (NASDAQ: VYGR) is a biotech in the medical sector that specializes in gene therapy for neurological diseases. Its shares took 
Via MarketBeat
J&J, Merck, Boston Scientific Debut Trio Of Splashy Takeovers Topping $3 Billion In Value
The year's biggest medical conference kicked off with a melee of buyout news. 
Via Investor's Business Daily
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
(NVS) - Analyzing Novartis's Short Interest
Via Benzinga
Novartis AG (NYSE: NVS) Records 52-Week High Friday Morning
Via Investor Brand Network
Google's AI Spin-Off Isomorphic Labs Strikes Big Pharma Deals, Paving the Way for Future of Drug Discovery
Isomorphic Labs, a London-based spin-out of Alphabet Inc (NASDAQ: GOOG) (NASDAQ: GOOGL) Google's AI R&D division DeepMind, has announced strategic part 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis
Isomorphic Labs will get upfront cash and milestone payments. 
Via Investor's Business Daily
Week In Review: 2024 Kicks Off With Three Deals Worth A Total Of $4 Billion
Suzhou Ribo Life Science formed a collaboration with Boehringer Ingelheim in a deal that could be worth up to $2 billion. Additionally, Allorion Therapeutics has out-licensed global rights (ex-China)... 
Via Talk Markets
Voyager Therapeutics Stock Tanked After-Hours - Here's Why
Voyager Therapeutics, Inc. (NASDAQ: VYGR) shares are trading lower in Thursday's after-hours session after announcing a proposed public offering  
Via Benzinga
Big Players' Recent Trades in NVS Options
Via Benzinga
(NVS) - Analyzing Novartis's Short Interest
Via Benzinga
VYGR Stock Alert: The $1.2 Billion Reason Voyager Therapeutics Is Up Today
VYGR stock is in focus as analysts expect more pharma deals in 2024, although some think these deals will be sunk by the Biden administration. 
Via InvestorPlace
Why Is Gene Therapy Focused Voyager Therapeutics Stock Soaring Today?
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), to advance pot 
Via Benzinga
Novartis Sweetens Its Deal With Voyager, And Voyager Stock — Up 25% — Flashes A Bullish Sign
The company inked an expanded collaboration deal with Novartis to test out gene therapies. 
Via Investor's Business Daily
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
Why Is Neurology Focused Cingulate Stock Trading Higher Today?
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance f 
Via Benzinga
Why Is Cytokinetics (CYTK) Stock Up 70% Today?
With Cytokinetics hitting a homerun with its heart failure drug, CYTK stock skyrocketed in part due to takeover interest. 
Via InvestorPlace
Bristol Myers Squibb Takes On Novartis, Eli Lilly With RayzeBio $4B Deal In Radiopharmaceuticals
Bristol Myers Squibb & Co (NYSE: BMY) has agreed to acquire RayzeBio Inc (NASDAQ: RYZB) for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of < 
Via Benzinga
These 3 Big Pharma Stocks Are Making Big Plays With AI
Opportunity is in the air with AI, and these pharma giants are seizing the moment. 
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Calliditas Therapeutics Scores Complete FDA Approval, Broader Label For Lead Kidney Disease Drug
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy... 
Via Benzinga
Exposures Product Safety
Fusion's Pharma's Targeted Cancer Therapy Potential Gets This Analyst Bullish, Sees 100% Upside
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a burgeoning area in therapeutics following the green light for Novartis... 
Via Benzinga
Lantheus Downgraded Due To Reliance On PNT2002; Analyst Cites Comparable Profile To Novartis' Drug
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivotal Phase 3 SPLASH trial of 177Lu-PNT2002 in metastatic c 
Via Benzinga
Are November’s 3 Biggest Stock Losers Worth Snapping Up Now?
The market was like an iceberg with only a few winners showing but that means there are a lot of the biggest stock losers worth getting now. 
Via InvestorPlace
FDA Approves Merck's Drug Belzutifan For Type Of Advanced Kidney Cancer In Pretreated Cancer Patients
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, for adult patients with advanced renal cell carcinoma (RCC) following a... 
Via Benzinga
Exposures Product Safety
Novartis' Newly FDA-Approved Rare Blood Disorder Drug Aces Phase 3 Study In Ultra Rare Kidney Failure Disease
Novartis AG (NYSE: NVS) announced  
Via Benzinga
This 1 Emerging Risk Could Be a Problem for These 3 Big Pharma Stocks
Regulators are already on the case, and their findings will have financial impacts. 
Via The Motley Fool
A Comprehensive Study Exploring Breast Cancer Treatment Market : Key Players Gilead Sciences, Astellas, Celgene
Get an extensive Breast Cancer Treatment Market analysis of the dominant vendors, their latest products and services, and the competitive landscape of the industry. 
Via SBWire
Zoetis Stock A Good Companion For Your Portfolio? Shares Rising
Reflecting strong fundamentals, Zoetis stock boasts a best-possible A SMR Rating (sales+profit margins+return on equity) on an A-to-E scale. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.